Titre
Medical treatment of migraine: from mechanisms of action to contraindications.
Type
synthèse (review)
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Higelin, F.
Auteure/Auteur
Annoni, J.M.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
0036-7672
Statut éditorial
Publié
Date de publication
1998
Volume
128
Numéro
10
Première page
374
Dernière page/numéro d’article
383
Peer-reviewed
Oui
Langue
anglais
Notes
Journal Article Review --- Old month value: Mar 7
Résumé
Management of migraine patients with or without aura must include appropriate medication to treat the attack and long-term preventive therapy, especially if the frequency of the attacks is greater than 2-4 per month. In both cases the choice of treatment depends on its efficacy and side effects. With regard to acute drug therapy, group studies do not suggest that ergot derivatives and sumatriptan are superior to simple analgesics and anti-inflammatory drugs, particularly if a prokinetic agent is added. These new substances are indicated for severe attacks refractory to more conventional therapy. Chronic drug abuse may induce drug-induced or rebound headaches. As regards long-term prophylaxis, group studies suggest that calcium antagonists and 5-HT-influencing drugs are superior concerning attacks frequency to beta-blocking agents, but involve very frequent side effects (weight gain and somnolence). Interesting preliminary results have also been reported with valproate and enalapril, which will confirmation by controlled studies. Finally, the choice of drug must take into account the patient's comorbidities (cardiovascular diseases, asthma, diabetes etc).
PID Serval
serval:BIB_F5F57B85AD06
PMID
Date de création
2008-01-25T10:37:11.385Z
Date de création dans IRIS
2025-05-21T06:26:38Z